i
Economics of vaccinating U.S. adults ≥60 years-old against respiratory syncytial virus updated summary comparing models from: GSK, Pfizer and University of Michigan-CDC
-
June 21, 2023
Details:
-
Personal Author:
-
Corporate Authors:
-
Conference Authors:
-
Subjects:
-
Document Type:
-
Name as Subject:
-
Genre:
-
Collection(s):
-
Main Document Checksum:
-
File Type:
Supporting Files
-
No Additional Files
More +